Characterising CD8+ T cell transcriptomic and clonal consequences of immune checkpoint blockade for the treatment of cancer

Characterising CD8+ T cell transcriptomic and clonal consequences of immune checkpoint blockade for the treatment of cancer

<p><b>Background:</b> Immune checkpoint blockade (ICB) is arguably the greatest advance in medical oncology this century. Nonetheless, responses are highly variable. Mechanistic insights into this heterogeneity promises to improve patient stratification and identification of thera...

Descripció completa

Dades bibliogràfiques
Autor principal:	Watson, RA
Altres autors:	Fairfax, B
Format:	Thesis
Idioma:	English
Publicat:	2023
Matèries:	Immunology Immuno-oncology Oncology, Experimental

Ítems similars

Immune Checkpoint Blockade sensitivity and Progression-Free Survival associates with baseline CD8+ T cell clone size and cytotoxicity
per: Watson, R, et al.
Publicat: (2021)

Zika virus oncolytic activity requires CD8+ T cells and is boosted by immune checkpoint blockade
per: Sharmila Nair, et al.
Publicat: (2021-01-01)

Dissecting peripheral CD8+ T cell responses and immune interactions during immune checkpoint blockade for metastatic melanoma
per: Tong, O
Publicat: (2023)

Clinical-genomic determinants of immune checkpoint blockade response in head and neck squamous cell carcinoma
per: Cristina Valero, et al.
Publicat: (2023-10-01)

Mathematical modelling and transcriptional characterisation of intratumoral regulatory T cell sub-populations
per: Muzhingi, I
Publicat: (2023)

Further Advances in Cancer Immunotherapy: Going Beyond Checkpoint Blockade
per: Robert W. Wilkinson, et al.
Publicat: (2018-06-01)

New approaches to treating cancer using immune-checkpoint blockade
per: Fellermeyer, M
Publicat: (2023)

FcγRIIB is a T cell checkpoint in antitumor immunity
per: Clara R. Farley, et al.
Publicat: (2021-02-01)

Combination systemic therapies with immune checkpoint inhibitors in pancreatic cancer: overcoming resistance to single-agent checkpoint blockade
per: Jun Gong, et al.
Publicat: (2018-10-01)

Treating ICB-resistant glioma with anti-CD40 and mitotic spindle checkpoint controller BAL101553 (lisavanbulin)
per: Vassilis Genoud, et al.
Publicat: (2021-11-01)

Linked CD4+/CD8+ T cell neoantigen vaccination overcomes immune checkpoint blockade resistance and enables tumor regression
per: Joseph S. Dolina, et al.
Publicat: (2023-09-01)

Blockade of the immunosuppressive KIR2DL5/PVR pathway elicits potent human NK cell–mediated antitumor immunity
per: Xiaoxin Ren, et al.
Publicat: (2022-11-01)

A cell-engineered system to assess tumor cell sensitivity to CD8+ T cell-mediated cytotoxicity
per: Nadine Nelson, et al.
Publicat: (2019-08-01)

IL-1 receptor–associated kinase-3 acts as an immune checkpoint in myeloid cells to limit cancer immunotherapy
per: Gürcan Tunalı, et al.
Publicat: (2023-04-01)

Exploiting 4-1BB immune checkpoint to enhance the efficacy of oncolytic virotherapy for diffuse intrinsic pontine gliomas
per: Virginia Laspidea, et al.
Publicat: (2022-04-01)

EBAG9 controls CD8+ T cell memory formation responding to tumor challenge in mice
per: Armin Rehm, et al.
Publicat: (2022-06-01)

Intrinsic RIG-I restrains STAT5 activation to modulate antitumor activity of CD8+ T cells
per: Xinyi Jiang, et al.
Publicat: (2023-05-01)

CD206+ tumor-associated macrophages cross-present tumor antigen and drive antitumor immunity
per: Madhura Modak, et al.
Publicat: (2022-06-01)

Bronchoalveolar lavage fluid reveals factors contributing to the efficacy of PD-1 blockade in lung cancer
per: Kentaro Masuhiro, et al.
Publicat: (2022-05-01)

Tumor-infiltrating exhausted CD8+ T cells dictate reduced survival in premenopausal estrogen receptor–positive breast cancer
per: Colt A. Egelston, et al.
Publicat: (2022-02-01)

CD7-deleted hematopoietic stem cells can restore immunity after CAR T cell therapy
per: Miriam Y. Kim, et al.
Publicat: (2021-08-01)

Decitabine priming increases anti–PD-1 antitumor efficacy by promoting CD8+ progenitor exhausted T cell expansion in tumor models
per: Xiang Li, et al.
Publicat: (2023-04-01)

Dual IL-6 and CTLA-4 blockade regresses pancreatic tumors in a T cell– and CXCR3-dependent manner
per: Michael Brandon Ware, et al.
Publicat: (2023-04-01)

Thromboembolic Events Related to Treatment with Checkpoint Inhibitors: Report of Two Cases
per: Jessica Tsukamoto, et al.
Publicat: (2018-10-01)

Preoperative immune checkpoint inhibition and cryoablation in early-stage breast cancer
per: Elizabeth Comen, et al.
Publicat: (2024-02-01)

Osteoimmuno-Oncology: Therapeutic Opportunities for Targeting Immune Cells in Bone Metastasis
per: Tiina E. Kähkönen, et al.
Publicat: (2021-06-01)

Multidimensional single-cell analysis identifies a role for CD2-CD58 interactions in clinical antitumor T cell responses
per: Gabrielle Romain, et al.
Publicat: (2022-09-01)

Editorial: Tumor microenvironment complexity and its therapeutic implications
per: Denner Santos dos Anjos, et al.
Publicat: (2025-01-01)

CD28 costimulation drives tumor-infiltrating T cell glycolysis to promote inflammation
per: Kathryn E. Beckermann, et al.
Publicat: (2020-08-01)

Circulating biomarkers in the diagnosis and prognosis of immune checkpoint inhibitor-related myocarditis: time for a risk-based approach
per: Gillian Murtagh, et al.
Publicat: (2024-02-01)

PD-1 and ICOS coexpression identifies tumor-reactive CD4+ T cells in human solid tumors
per: Rebekka Duhen, et al.
Publicat: (2022-06-01)

Systemic inflammation is a determinant of outcomes of CD40 agonist–based therapy in pancreatic cancer patients
per: Max M. Wattenberg, et al.
Publicat: (2021-03-01)

Immune regulatory networks in inflammation-driven cancer
per: Franchini, F
Publicat: (2017)

Immune determinants of Barrett’s progression to esophageal adenocarcinoma
per: Kiran H. Lagisetty, et al.
Publicat: (2021-01-01)

Tumor cells fail to present MHC-II–restricted epitopes derived from oncogenes to CD4+ T cells
per: Spencer E. Brightman, et al.
Publicat: (2023-01-01)

CXCL13-producing CD4+ T cells accumulate in the early phase of tertiary lymphoid structures in ovarian cancer
per: Masayo Ukita, et al.
Publicat: (2022-06-01)

A PDGFRB- and CD40-targeting bispecific AffiMab induces stroma-targeted immune cell activation
per: Alessandro Mega, et al.
Publicat: (2023-12-01)

IL-32γ potentiates tumor immunity in melanoma
per: Thomas Gruber, et al.
Publicat: (2020-09-01)

Anti–PD-L1 and anti-CD73 combination therapy promotes T cell response to EGFR-mutated NSCLC
per: Eric Tu, et al.
Publicat: (2022-02-01)

A bispecific anti-PD-1 and PD-L1 antibody induces PD-1 cleavage and provides enhanced anti-tumor activity
per: Diana I. Albu, et al.
Publicat: (2024-12-01)